Ochsner Health physicians Dr. Richard Zweifler and Dr. Joseph Tarsia are co-authors on a post hoc analysis carried out in the ARCADIA randomized clinical trial, comparing the effectiveness of apixaban versus aspirin in preventing adverse clinical outcomes in patients with a history of cancer and cryptogenic stroke.
The research found no significant difference in the risk of major ischemic and hemorrhagic events between those taking apixaban and aspirin. The study was published in the JAMA Neurology journal. The ARCADIA study was a multicenter, double-blind, randomized clinical trial conducted between 2017 and 2020.
The primary outcome measure was a composite of major ischemic and hemorrhagic events, including ischemic stroke , systemic embolism, myocardial infarction , or vascular death. A total of 1,015 participants were enrolled in the trial and followed up for a median duration of 11.1 months.
Participants in the study were adults with recent cryptogenic stroke and biomarker evidence of atrial cardiopathy, such as an enlarged left atrium or high levels of natriuretic peptides. They also had a history of cancer within the past ten years. The findings of this post hoc analysis suggest that both apixaban and aspirin may be effective in preventing adverse clinical outcomes in patients with a history of cancer and cryptogenic stroke.
However, further studies are needed to confirm these results and determine the optimal treatment for this patient population. "Our findings from t.